CELL & GENE THERAPY INSIGHTS

Scaling up/out: cost-effective and robust transitioning through the clinic to commercial manufacture

Guest Editor:
Jan Thirkettle, Chief Executive Officer at Transine Therapeutics
Jan Thirkettle
Chief Executive Officer at Transine Therapeutics
September 2020